Despite differences in enrollment criteria, the baseline characteristics of the menopausal women with coronary heart disease enrolled in the cardiovascular outcome trials of menopausal hormone therapy or raloxifene are remarkably similar. Globally, cardiovascular risk factors were not optimally controlled at entry into these trials. More aggressive cardiovascular risk factor interventions are requisite to achieve optimal target goals for women with documented coronary heart disease.